Sector consensus Outlook Therapeutics, Inc.
Stocks
OTLK
US69012T3059
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.6449 USD | +0.59% |
|
-0.36% | -59.18% |
| 08-27 | Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 | CI |
| 08-27 | Outlook Therapeutics Appoints Kevin Lundquist as CFO | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 4.9 | +659.81% | 4 | ||||||
| 681.13 | +16.67% | 23 | ||||||
| 247.11 | +18.87% | 21 | ||||||
| 275.17 | +5.13% | 18 | ||||||
| 432.16 | +17.84% | 28 | ||||||
| 266,031.64 | +39.5% | 23 | ||||||
| 581.83 | -3.13% | 12 | ||||||
| 271.49 | +27.58% | 20 | ||||||
| 72.53 | +0.23% | 14 | ||||||
| 281 | -3.6% | 14 | ||||||
| 185.56 | +9.14% | 16 | ||||||
| 63.36 | -1.07% | 14 | ||||||
| 70.73 | -2.24% | 11 | ||||||
| 49.79 | +13.73% | 11 | ||||||
| 138.97 | +42.68% | 6 | ||||||
| 134.85 | -0.09% | 11 | ||||||
| 88 | +44.14% | 22 | ||||||
| 132.5 | +12.15% | 22 | ||||||
| 3.72 | -16.71% | 7 | ||||||
| 638.68 | +85.26% | 19 | ||||||
| Average | 13,519.26 | +48.29% | 16 | ||||||
| Weighted average by Cap. | 23,426.68 | +16.55% | 19 |
- Stock Market
- Stocks
- OTLK Stock
- Sector Outlook Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
